TScan Therapeutics, Inc. reports clinical and corporate developments for its T cell receptor-engineered T cell therapy pipeline. The company’s cancer programs include TSC-101 in the ALLOHA heme trial for patients with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation, and CD45-targeted candidates TSC-102-A01 and TSC-102-A03 with cleared IND applications.
Recurring TCRX updates cover clinical data presentations, trial enrollment and manufacturing-process updates, FDA interactions, financial results, healthcare conference participation, and portfolio priorities. The company also describes early work in in vivo engineering for solid tumors and target discovery in T cell-mediated autoimmune disorders.
TScan Therapeutics (TCRX) announced a strategic reorganization to prioritize its in vivo-engineered TCR-T solid tumor program, advancing two candidates targeting PRAME and MAGE-A4 into IND-enabling studies.
The company plans to share preclinical data in Q1 2027, file its first IND in Q3 2027, and initiate Phase 1 development in Q4 2027. Updated Phase 1 ALLOHA™ Cohort C data for TSC-101 in heme malignancies show 100% (13/13) of tracked patients with complete donor chimerism, with infusions generally well tolerated. Due to capital constraints, TScan has paused further enrollment in the Phase 3 ALLOHA-2™ study and is pausing the heme malignancies program while seeking partners. The reorganization includes eliminating internal manufacturing, reducing research footprint, and a workforce reduction of approximately 75%, targeting cumulative cost savings of $55 million through 2027 and extending cash runway into Q4 2027.
TScan Therapeutics (Nasdaq:TCRX) reported second quarter 2026 revenue of $1.1 million, down from $3.1 million a year earlier, and a net loss of $30.4 million versus $37.0 million in 2025, as R&D and G&A expenses declined to $23.4 million and $8.1 million, respectively.
The company dosed the first patient in its pivotal Phase 3 ALLOHA-2™ trial of TSC-101, targeting topline data in mid-2028, and shared positive Cohort C data from the Phase 1 ALLOHA™ study, including ~90% manufacturing success and 79% complete donor chimerism. Cash and cash equivalents were $100.2 million at June 30, 2026, which TScan believes will fund operations into the second quarter of 2027, reflecting upcoming term loan amortization starting in the fourth quarter of 2026.
TScan Therapeutics (Nasdaq: TCRX) reported dosing the first patient with TSC-101 in its pivotal Phase 3 ALLOHA-2™ trial (NCT07702578), which is actively enrolling patients across the US and has an anticipated topline data readout in mid-2028.
The study evaluates TSC-101 for treating residual disease to prevent relapse after allogeneic hematopoietic cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). According to TScan, initial Phase 1 ALLOHA™ Cohort C data using the commercial-ready process showed strong clinical efficacy and a positive safety profile, supporting progression to Phase 3. ALLOHA-2 compares standard-of-care HCT plus TSC-101 versus HCT alone, using biological assignment based on A*02:01 status and donor availability. All subjects receive reduced-intensity conditioning, and treatment-arm patients get two TSC-101 infusions post-engraftment. The primary endpoint is relapse-free survival, with overall and event-free survival as key secondary endpoints.
TScan Therapeutics (Nasdaq:TCRX), a clinical-stage biotech developing TCR-T cell therapies for cancer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026 at 11:30 a.m. ET.
A live webcast and 90-day replay will be available on TScan's investor relations website.
TScan Therapeutics (Nasdaq:TCRX) reported initial Cohort C data from the ALLOHA™ Phase 1 study of TSC-101 in heme malignancy patients undergoing allo-HCT. Of 19 enrolled patients, 17 had successful manufacturing and 14 received a first infusion; 11/14 achieved complete donor chimerism within ~3 weeks. Safety remained generally well-tolerated and consistent with prior experience. TScan remains on track to enroll the first patient in the pivotal ALLOHA-2™ Phase 3 study this month and is hosting a virtual KOL event on June 22, 2026.
TScan Therapeutics (Nasdaq:TCRX) and Cellares entered an agreement to evaluate automated clinical manufacturing of TSC-101, a TCR-T therapy candidate for patients with AML and MDS undergoing allo-HCT.
The collaboration uses Cellares’ Cell Shuttle and Cell Q platforms to assess a scalable, cost-efficient path to commercialization as TSC-101 advances toward a pivotal trial expected to begin in Q2 2026.
TScan Therapeutics (Nasdaq: TCRX) reported Q1 2026 results and a corporate update. Revenue was $1.0M; R&D expense $21.9M; G&A $8.2M; net loss $28.7M. Cash and cash equivalents were $128.1M, funding operations into the second half of 2027.
Clinical milestones: early Cohort C ALLOHA data expected Q2 2026; Phase 3 initiation of TSC-101 planned Q2 2026; Phase 1 starts for TSC-102-A01/A03 targeted for H2 2026; ASGCT poster on CD45 TCRs in May 2026.
TScan Therapeutics (Nasdaq: TCRX) will present a poster at the American Society of Gene and Cell Therapy 29th Annual Meeting, May 11–15, 2026 in Boston and virtually. The poster, Abstract ID 1256, covers CD45-targeted TCR-T therapies to address residual disease after allogeneic hematopoietic cell transplantation. The poster session is Tuesday, May 12 with a reception 5:00–6:30 p.m. ET in the Poster Hall at the Thomas M. Menino Convention & Exhibition Center. Presentation materials will be posted to the company’s Publications page at tscan.com after the event.
TScan Therapeutics (Nasdaq: TCRX) will present in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 3:00 p.m. ET. A live webcast will stream at the company’s Events and Presentations page and an archived replay will be available for 90 days.
TScan Therapeutics (Nasdaq: TCRX) reported Q4 and full‑year 2025 results and a heme‑program update on March 4, 2026. Key items: IND clearances for TSC‑102‑A01 and TSC‑102‑A03, completion of Cohort C enrollment for ALLOHA™ using commercial manufacturing, and a cash runway into H2 2027.
Financials: Q4 revenue was $2.6M (Q4 2024: $0.7M); FY2025 revenue was $10.3M (FY2024: $2.8M). Pro forma shares including pre‑funded warrants totaled 129.9M as of Dec 31, 2025.